Literature DB >> 1534804

Characterization of mitotically phosphorylated caldesmon.

Y Yamakita1, S Yamashiro, F Matsumura.   

Abstract

Mitosis-specific phosphorylation by cdc2 kinase causes nonmuscle caldesmon to dissociate from microfilaments (Yamashiro, S., Yamakita, Y., Ishikawa, R., and Matsumura, F. (1990) Nature 344, 675-678; Yamashiro, S., Yamakita, Y., Hosoya, H., and Matsumura, F. (1991) Nature 349, 169-172). To explore the function of mitosis-specific phosphorylation of caldesmon, in vivo- and in vitro-phosphorylated caldesmons have been characterized. We have found that both in vivo and in vitro phosphorylation of caldesmon causes similar changes in the properties, including reduction in actin, calmodulin, and myosin binding of caldesmon, and a decrease in the inhibition of actomyosin ATPase by caldesmon. Rat non-muscle caldesmon is phosphorylated in vitro up to a ratio of 7 mol/mol of protein. Actin-binding constants of both a high affinity (K a = 1.2 x 10(7) M-1) and a low affinity (K a = 1 x 10(6) M-1) site of unphosphorylated caldesmon are reduced to less than 10(5) M-1 with 5 mol of phosphate incorporation per mol of protein. Actin-bound caldesmon can be phosphorylated by cdc2 kinase, which results in the dissociation of caldesmon from F-actin. Caldesmon has a second myosin-binding site in the C terminus, in addition to the N terminus myosin-binding domain previously reported, because the bacterially expressed C terminus of caldesmon shows binding to myosin. Phosphorylation of the C-terminal fragments decreases their myosin-binding affinity as observed with intact caldesmon. These results suggest that caldesmon loses most of its in vitro functions during mitosis as a result of phosphorylation, which may be required for the reorganization of microfilaments during mitosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534804

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Mutant Caldesmon lacking cdc2 phosphorylation sites delays M-phase entry and inhibits cytokinesis.

Authors:  S Yamashiro; H Chern; Y Yamakita; F Matsumura
Journal:  Mol Biol Cell       Date:  2001-01       Impact factor: 4.138

2.  A transformation-associated complex involving tyrosine kinase signal adapter proteins and caldesmon links v-erbB signaling to actin stress fiber disassembly.

Authors:  M J McManus; W L Lingle; J L Salisbury; N J Maihle
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  Both N-terminal myosin-binding and C-terminal actin-binding sites on smooth muscle caldesmon are required for caldesmon-mediated inhibition of actin filament velocity.

Authors:  Z Wang; H Jiang; Z Q Yang; S Chacko
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

4.  Identification of functioning regulatory sites and a new myosin binding site in the C-terminal 288 amino acids of caldesmon expressed from a human clone.

Authors:  P A Huber; C S Redwood; N D Avent; M J Tanner; S B Marston
Journal:  J Muscle Res Cell Motil       Date:  1993-08       Impact factor: 2.698

5.  Phosphorylation of aorta caldesmon by endogenous proteolytic fragments of protein kinase C.

Authors:  A V Vorotnikov; N B Gusev; S Hua; J H Collins; C S Redwood; S B Marston
Journal:  J Muscle Res Cell Motil       Date:  1994-02       Impact factor: 2.698

6.  Overexpression, purification, and characterization of full-length and mutant caldesmons using a baculovirus expression system.

Authors:  Z Wang; K Y Horiuchi; S S Jacob; S Gopalakurup; S Chacko
Journal:  J Muscle Res Cell Motil       Date:  1994-12       Impact factor: 2.698

7.  Identification of multiple genes in bovine retinal pericytes altered by exposure to elevated levels of glucose by using mRNA differential display.

Authors:  L P Aiello; G S Robinson; Y W Lin; Y Nishio; G L King
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

Review 8.  Caldesmon as a therapeutic target for proliferative vascular diseases.

Authors:  Chi-Ming Hai
Journal:  Mini Rev Med Chem       Date:  2008-10       Impact factor: 3.862

9.  Reversal of caldesmon binding to myosin with calcium-calmodulin or by phosphorylating caldesmon.

Authors:  M E Hemric; F W Lu; R Shrager; J Carey; J M Chalovich
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

Review 10.  Smooth muscle signalling pathways in health and disease.

Authors:  H R Kim; S Appel; S Vetterkind; S S Gangopadhyay; K G Morgan
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.